Patent Application
20140336282
The present invention relates to the field of cancer. More specifically, the present invention provides assays for identifying molecular signatures of invasive cancer subpopulations.
The large majority of cancers in the United States initiate from epithelial cells. In these epithelial cancers the major clinical problem is metastasis. A major unsolved challenge is determining which of the many cell epithelial cell types are most important to the tumor's ability to invade, metastasize, and resist therapy. Most efforts to classify the relative ability of cancer cells to initiate tumors or to metastasize to distant sites rely on sorting the cells based on cell surface markers prior to analysis. The sorting can be accomplished by Fluorescence Activated Cell Sorting (FACS) or by Magnetic Activated Cell Sorting (MACS). However, in either case the researcher needs to decide in advance how to identify the cell population to be tested and cell populations can only be compared that both survive the sorting process and for which reliable cell surface markers or other fluorescent reporters can be developed. Accordingly, these approaches may fail to identify the cancer cell subpopulations that are actually driving the functional properties of the tumor.
Epithelial tumors are heterogeneous and contain many different epithelial and stromal cell populations. Work in recent years has focused on identifying stromal cell populations in the tumor microenvironment that can modify the invasive, metastatic or therapeutic resistance properties of the tumor. Comparatively less is known about the different epithelial populations within solid tumors. The present invention is based, at least in part, on the development of techniques for isolating tissue from primary tumors for live culture while retaining the natural diversity of epithelial cell types. We have further developed assays that enable stratification of the cancers cells based on their invasive behavior. Importantly, the stratification is prospective and we do not require a priori molecular knowledge, or cell surface marker-based sorting, of the epithelial populations in advance of the invasion assays. We have both developed techniques to prospectively identify the most invasive cells in a solid tumor and we have also developed specific molecular signatures for invasive subpopulations based on work in multiple mouse models of mammary carcinoma.
We have developed protocols to identify the most invasive populations within epithelial tumors using 3D culture techniques that establish a competitive invasion and metastasis assay within 2D or 3D microenvironments composed of extracellular matrix proteins. We have extensively evaluated our assay in a mouse model of mammary carcinoma and have used it to identify a novel and rare (˜10% of epithelial cells) cell populations that robustly leads invasion in 3D culture, is positioned at the front of invasive strands in vivo, is the dominant cell type in lung micrometastases, and appears to be more resistant to therapy. We have therefore both developed a general approach for prospectively identifying the most invasive epithelial cell populations within a tumor and have developed a novel molecular signature for a specific subpopulation (keratin-14+, p63+, P-cadherin+, smooth muscle alpha actin−). We have then used the molecular signature we developed to identify this novel subpopulation in each of three additional mouse mammary carcinoma models we have tested. Importantly, this novel highly invasive subpopulation is present in both luminal and basal mammary carcinomas suggesting it may be a therapeutically important cell type in multiple subtypes of human breast cancer.
In preliminary experiments this novel basal cell population is also more resistant to therapy than the bulk K14− cells in the tumor. Combined with the overrepresentation of these novel basal cells in lung micrometastases, our data suggest that the most invasive cell population in our assay predicts the molecular features of distributed lung metastases. A major clinical problem in epithelial cancers is developing treatment regimens capable of eliminating distributed micrometastases, many of which will be undetectable at the time of adjuvant chemotherapy. Knowing the molecular characteristics of this population could aid in designing personalized treatment regimens for individual patients that are more likely to achieve curative results. Since it is typically not possible to sample directly the micrometastatic sites in a patient our assays enable isolation of a surrogate for these sites based on much more readily available tissue from the primary tumor.
Our assays: (1) enable efficient live culture of primary tumor tissue with retention of the varied epithelial cell types; (2) enable prospective identification of the most invasive epithelial cell populations without requiring prior knowledge of the cells' molecular characteristics; and (3) enable ready recovery of the most invasive cell populations for molecular characterization. In addition, we can collect thousands of epithelial fragments per tumor and so can work in parallel to identify the invasive subpopulations, determine their relative abundance, and test their sensitivity to different chemotherapies. Finally, our assay has been optimized for multiwell plate format.
Accordingly, in one aspect, the present invention provides methods for characterizing invasive cells within tumors. In one embodiment, a method for characterizing invasive cells within primary tumors comprises the steps of (a) isolating primary tumors from a subject; (b) generating tumor organoids via mechanical disruption and/or enzymatic digestion; (c) culturing tumor organoids in an extracellular matrix gel; and (d) determining the molecular phenotype of the cells leading the invasive strands of the cultured tumor organoids using gene expression profiling. In certain embodiments, the extracellular matrix gel is a collagen I gel. In particular embodiments, the extracellular matrix gel is a three-dimensional extracellular matrix gel.
In another aspect, the present invention provides methods for treating cancer patients. In one embodiment, a method for treating a patient having a primary tumor comprises the steps of (a) isolating tissue from the patient's tumor; (b) culturing the tissue in an extracellular matrix gel; (c) determining the molecular phenotype of the cells leading the invasive strands of the cultured tumor organoids using gene expression profiling; and (e) treating the patient based on the identity of the molecular phenotype of the invasive cells. In a specific embodiment, the extracellular matrix gel is a collagen I gel. In particular embodiments, the extracellular matrix gel is a three-dimensional extracellular matrix gel. In another embodiment, a method for treating a patient having a tumor comprising basal leader cells comprises the step of administering to the patient an agent that inhibits keratin 14 and/or p63.
In a further embodiment, a method for treating a patient having a primary tumor comprises the steps of (a) isolating tissue from the patient's tumor; (b) culturing the tissue in an extracellular matrix gel; (c) determining the molecular phenotype of the cells leading the invasive strands of the cultured tumor organoids using gene expression profiling; and (d) testing the invasive cells using one or more cancer treatments; and (e) treating the patient based on the cancer treatment that shows the best success rate in step (d). In particular embodiments, the extracellular matrix gel is a three-dimensional extracellular matrix gel.
The present invention also provides methods for estimating the likelihood of distant metastases of a primary tumor in a patient comprising the steps of (a) isolating tissue from the patient's tumor; (b) culturing the tissue in an extracellular matrix gel; and (c) estimating the likelihood and/or rate of metastatic spread based on the frequency of invasion in the cell culture. In a specific embodiment, the extracellular matrix gel is a collagen I gel. In particular embodiments, the extracellular matrix gel is a three-dimensional extracellular matrix gel.
In yet another aspect, the present invention provides methods for identifying subpopulations of cells. In one embodiment, a method for identifying invasive subpopulations in sections from fixed tissue from archival human tumor sections comprises the step of staining for a basal leader signature comprising keratin 14+, p63+, P-cadherin+, and smooth muscle actin−. In another embodiment, a method for identifying invasive subpopulations in sections from fixed tissue from archival human tumor sections comprises analyzing mRNA expression signatures for a basal leader signature comprising keratin 14+, p63+, P-cadherin+, and smooth muscle actin−. In other embodiments, the signature comprises K14+. In certain embodiments, the signature further comprises one or more of, p63+, P-cadherin+, and smooth muscle actin−. In a specific embodiment, the tumor is a carcinoma. In other embodiments, the carcinoma is basal cell carcinoma, squamous cell carcinoma, renal cell carcinoma, ductal carcinoma in situ, invasive ductal carcinoma, or adenocarcinoma. The adenocarcinoma can be include, but is not limited to, breast, hepatocellular, prostate, colon and lung.
It is understood that the present invention is not limited to the particular methods and components, etc., described herein, as these may vary. It is also to be understood that the terminology used herein is used for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention. It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include the plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to a “protein” is a reference to one or more proteins, and includes equivalents thereof known to those skilled in the art and so forth.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Specific methods, devices, and materials are described, although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention.
All publications cited herein are hereby incorporated by reference including all journal articles, books, manuals, published patent applications, and issued patents. In addition, the meaning of certain terms and phrases employed in the specification, examples, and appended claims are provided. The definitions are not meant to be limiting in nature and serve to provide a clearer understanding of certain aspects of the present invention.
Invasion is a fundamental step in tumor progression and a driving force for metastasis. Although invasion is commonly conceptualized as a single-cell process, the majority of solid tumors display features of collective invasion in which cells invade cohesively as a multicellular unit (Friedl et al., 2012; Leighton et al., 1960). A central problem in collective invasion is how a group of adherent epithelial cancer cells acquires motile invasive behavior (Friedl and Gilmour, 2009; Gray et al., 2010; Polyak and Weinberg, 2009).
One solution is for cancer cells to rely upon the motility of migratory stromal cells, such as fibroblasts (Gaggioli et al., 2007) or macrophages (Condeelis and Pollard, 2006; DeNardo et al., 2009). However, mammary tumors also contain multiple subpopulations of tumor cells with distinct genotypic and phenotypic characteristics. Importantly, this cellular heterogeneity is associated with differences in metastatic potential and therapeutic response (Almendro et al., 2013; Fidler, 2003). It remains unclear how these subpopulations of cancer cells contribute to collective invasion.
Clinically, the transition from in situ to invasive breast cancer correlates with a strong reduction in overall survival, but the molecular basis of this transition has remained elusive (Polyak, 2010). The challenge of transitioning to a motile phenotype is particularly acute in mammary lumenal epithelial cells, as these cells are normally connected by extensive intercellular junctions and display less spontaneous motility than myoepithelial cells in real-time analyses (Ewald et al., 2008). Consistent with this concept, lumenal breast cancers have a more favorable average prognosis, but 10%-20% of cases eventually metastasize to liver, lung, or brain (Kennecke et al., 2010). Furthermore, luminal breast cancer cell lines are weakly invasive in 2D culture compared to basal subtypes (Neve et al., 2006).
We hypothesize that breast tumors accomplish collective invasion through cell-cell interactions among functionally distinct epithelial cancer cells within the primary tumor. To test this hypothesis, we developed 3D organoid assays to identify the most invasive cancer cells within a primary tumor in an unbiased fashion. In the present study, we applied these assays to demonstrate that the cells leading collective invasion are molecularly and behaviorally distinct from the bulk tumor cells and display a conserved, basal epithelial gene expression program.
The classic view of epithelial cancers was based on the assumption that phenotypically and genetically similar cancer cells were responsible for the majority of the important cellular and molecular attributes of a cancer cell. This is most strongly represented in the case of chronic myeloid leukemia in which a single molecular event (chromosomal translocation) creates an abnormal fusion protein that is diagnostic for the disease and required for its function. Most epithelial cancers instead exhibit considerable cellular and molecular heterogeneity among the cancer cells. This “tumor heterogeneity” is increasingly appreciated, but relatively few groups have proposed strategies to determine which of these various cancer genotypes and phenotypes are most important to disease progression.
The present inventors hypothesized that 3D culture models could be used to prospectively identify the most invasive cancer cells based on their behavior and functional attributes. We then used molecular techniques to describe these cells. The present inventors have also simplified the assay to capture the type of invasive behavior described herein. For example, in one embodiment, a thin pattern of collagen I can be laid on a glass coverslip and cells plated on top. Thus, in certain embodiments, the organoids/tissue/cells are cultured in an extracellular matrix gel. In certain embodiments, the extracellular matrix gel is a three-dimensional extracellular matrix gel.
The critical difference from past efforts is that the functional ability of the cancer cells to invade is the primary focus of the present assay; the molecular phenotype is the description of the cells that share this functional attribute. Previous approaches have almost all used one assay or another to purify a population with a specific molecular phenotype and then compare it to unsorted or alternately sorted populations. The limitation of that approach is that one needs to select the molecules in advance and a lot of time may be spent describing cellular populations that are more proliferative/invasive, etc. than the bulk average but nonetheless are not the cells that really dictate proliferation and invasion in vivo. Extensive experimental work by the present inventors has validated that the approach works and that the most invasive cells in 3D culture are also the most invasive in vivo and that they are strongly overrepresented in metastases.
The invasion assays of the present invention can also be used in the laboratory setting as an experimental tool. BD and others sell Matrigel-Invasion Kits, which have questionable physiologic relevance to in vivo invasion. The present invention represents a clear conceptual advance over other more primitive invasion assays, like the matrigel-invasion kits. More importantly, the present invention has been actually validated in vivo, such that we identify morphologically similar invasion at the invasive border and in specific matrix micro-environments. The assays of the present invention could replace Matrigel-Invasion as the new gold-standard for assaying invasion.
Accordingly, in one aspect, the present invention provides assays for identifying the invasive subpopulation(s) of a tumor. Researchers have been explanting cells and tissues into 2D and 3D ECM gels for decades. However, the present inventors are the first to couple this technology with the idea that these assays can be used to identify the most invasive cells in a tumor by their functional behavior. In one embodiment, the present invention can be used to identify invasive subpopulations in additional epithelial cancers (e.g., what is the most invasive cell type in a lung cancer). In another embodiment, the present invention may comprise personalized medicine assay based on a patient's own live tumor tissue to determine the identity and abundance of invasive subpopulations in their primary tumor. In yet another embodiment, the present invention may comprise a personalized medicine assay to determine the chemosensitivity of a patient's own metastases. We have shown that invasive leaders can be rare in the primary tumor but are typical of the metastatic site. Accordingly, the chemosensitivity of these cells to different therapies could be tested and the response of the patient's metastases can be predicted. This is distinct from past chemosensitivity proposals as it focuses on identifying a specific cancer cell subpopulation.
In further embodiments, the present invention can be used to quantify the fraction of cells in the tumor that can convert to K14+ when explanted into the assay. In other embodiments, the convertibility assay could be used for any molecular signature of invasive behavior. More specifically, the assay captures the fraction of cells in a tumor capable of initiating metastatic spread. The wide variation in inducibility of primary human breast tumors is captured in
In another aspect, the present invention contemplates that the molecular signature described herein (K14+, p63+, etc.) is characteristic of all highly invasive epithelial cancer cells. In one embodiment, the signature comprises keratin 14+, p63+, P-cadherin+, smooth muscle actin−. In other embodiments, each one of keratin 14+, p63+, P-cadherin+, and smooth muscle actin− can serve as a molecular marker. In a specific embodiment, K14+ is the biomarker, and so on. Accordingly, this subpopulation represents a target for cancer therapy.
In another aspect, the abundance and/or locations of invasive leader cells correlates with patient progress. The molecular signature described herein can be used as a biomarker to assess individualized risk of recurrence/distant metastasis.
In yet another aspect, the present invention provides agents for modulating targets involved in the basal invasive molecular program. We have identified not only the cell type, but also specific molecular targets. Specifically, we define the cell population (basal leaders) as important for invasion, but also define specific molecular targets whose inhibition may have therapeutic benefits in blocking invasion and metastasis. We have identified multiple molecular targets that when inhibited result in either a block of the invasive program (e.g. p90RSK or p63) or a block of the invasive behavior of invasive leader cells (e.g. K14, FAK, Src). We have shown that shRNA inhibition of K14 blocks invasion in vitro and in vivo. We have identified small molecule inhibitors of multiple of these targets (e.g. FAK inhibitor (Pfizer).
In particular embodiments, the present invention provides assays that enables prospective identification of the most invasive cancer cells within a tumor and their subsequent molecular characterization. The present invention can be used to detect the molecular signature of a specific population of invasive cells first identified from our studies, which we call basal leader cells.
In certain embodiments, live tissue from a patient's own tumor can be harvested and cultured in this assay to reveal the most invasive cells in that patient's tumor. In mouse models, the most invasive population in the live cell assay predicted the cellular identity of micrometastases at distant sites in the body. In addition, the frequency of invasion in the live cell assay between mouse models appears to correlate with the published rate of metastatic spread to the lungs. The live cell assay therefore provides an ability to estimate the likelihood of distant metastases as well as to predict the molecular characteristics of those cells. The cellular identity of the most invasive population could be used to estimate risk of recurrence or to personalize the course of treatment for the patient. If the cellular identity corresponds to basal leader cells, we predict an increased risk of recurrence and resistance to chemotherapy.
We have defined a specific molecular signature, the basal leader signature, (keratin 14+, p63+, P-cadherin+, smooth muscle actin−) that correlates with the most invasive subpopulation in mouse tumor models and with the cellular identity of micrometastases. This gene expression signature could be used to identify invasive subpopulations in sections from fixed tissue from archival human tumors. Alternatively, the presence of this gene signature could be determined by mRNA expression analysis from archival sections to generate a composite score. If validated in large cohorts this gene signature could be developed into a diagnostic assay based on the composition and abundance of different highly invasive subpopulations within the tumor. This gene expression information could then be used to estimate the risk of local recurrence or distant metastases. The signature can also comprise individually each of the markers listed above, e.g., K14+.
A major barrier to the development of therapies to limit the invasive and motile properties of cancer cells is our very incomplete understanding of the cell and tissue basis of cancer invasion in vivo. The critical events of invasion, dissemination, systemic spread, and establishment of distant metastases occur episodically, deep within the body over a period of months to years. Recent work from multiple labs, including our own, has led to the in vivo observation of cell dynamics in intact mammary tumors. A surprising result of these studies was that most cancer cells in established epithelial tumors were non-motile. Histological examination of breast tumors has revealed striking cellular and molecular heterogeneity, but analysis of fixed sections cannot distinguish the relative contributions of these subpopulations to invasion. To solve this problem, we developed a suite of isolation, culture, gene manipulation, and imaging techniques to enable the real-time analysis of invasion and dissemination in primary tumors within 3D tumor microenvironments. We developed protocols for culturing normal epithelium and mammary tumors from primary mouse and human sources. We explant primary epithelial fragments (500-1000 cells each) into 3D extracellular matrix (ECM) gels (
We explanted metastatic mammary carcinomas (MMTV-PyMT) into Matrigel and observed confined growth without dissemination in Matrigel and vigorous sustained dissemination into collagen I. It was known that smooth muscle actin (SMA) positive myoepithelial cells are lost early in this model, paralleling human luminal B breast cancer. We next conducted a systematic RNA expression analysis of normal and tumor tissue growing in both matrices and observed that the contractile smooth muscle program was lost, but that the majority of other myoepithelial specific genes (e.g. keratin-14 (K14)) displayed only modest reductions. Our imaging studies revealed that the most common leaders cells during invasion in 3D culture are epithelial cells that express basal markers (K14+), but lack the mature smooth muscle program (SMA−,
Mature myoepithelial cells function as tumor suppressors, but aggressive basal subtype cancers express a subset of myoepithelial markers. Recent studies have focused on the role of stromal cells in leading breast tumor invasion. We previously revealed that normal myoepithelial cells have higher intrinsic motility than luminal cells and our current data suggest that mammary tumors co-opt this motility program. Our working hypothesis is that basal epithelial subpopulations can lead the invasion and metastasis of breast tumors, including in luminal subtypes. Our data identify biological heterogeneity within the epithelial cells of the tumor as a potential driving force for metastasis and suggest even a small basal subpopulation can have a large effect on the dynamics of a luminal breast tumor. Our work could have particular importance for patients with metastatic breast cancer, as long-term control of tumor invasion and metastasis will likely require suppression of each potential leader population.
In one embodiment, tumors are surgically isolated and then minced with a sterile scalpel. Tumors are enzymatically digested in a mixture of collagenase and trypsin to yield small “organoids” that contain 500-1000 tumor cells. These organoids are then explanted into 3D gels of extracellular matrix proteins, most typically collagen I gels. Over time in culture invasive strands emerge from the organoids and the invasive leaders can be molecularly profiled in situ or following laser capture or other microdissection techniques.
Without further elaboration, it is believed that one skilled in the art, using the preceding description, can utilize the present invention to the fullest extent. The following examples are illustrative only, and not limiting of the remainder of the disclosure in any way whatsoever.
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices, and/or methods described and claimed herein are made and evaluated, and are intended to be purely illustrative and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some errors and deviations should be accounted for herein. Unless indicated otherwise, parts are parts by weight, temperature is in degrees Celsius or is at ambient temperature, and pressure is at or near atmospheric. There are numerous variations and combinations of reaction conditions, e.g., component concentrations, desired solvents, solvent mixtures, temperatures, pressures and other reaction ranges and conditions that can be used to optimize the product purity and yield obtained from the described process. Only reasonable and routine experimentation will be required to optimize such process conditions.
Mouse Lines and Breeding.
Mice used in this study were backcrossed onto and maintained on the FVB/n background in a specific pathogen-free facility Animal protocols were approved by the Johns Hopkins IACUC. FVB/N-Tg(MMTV-PyVT)634Mul/J (MMTV-PyMT) (Guy et al., 1992a), FVB/N-Tg(MMTVneu)202Mul/J (MMTV-Neu) (Guy et al., 1992b), FVB-Tg(C3-1-TAg)cJeg/JegJ (C3(1)/Tag) (Maroulakou et al., 1994), and B6.129(Cg)-Gt(ROSA)26Sortm4(ACTBtdTomato,−EGFP)Luo/J (mT/mG) (Muzumdar et al., 2007) mice were obtained from the Jackson Lab. K14-GFP− actin mice (Vaezi et al., 2002) were a generous gift from Elaine Fuchs (Rockefeller University). For confocal timelapse experiments, MMTV-PyMT mice were crossed with mT/mG mice and/or K14-GFP− actin mice.
Analyses of Fresh Primary Human Tumors.
Primary breast cancers were acquired in accordance with IRB exempt protocols NA—00052607 and NA—00077976 (Nguyen-Ngoc et al., 2012). In brief, each tumor sample was deidentified prior to receipt with limited prespecified clinical information provided with each sample. The tumor sample was kept in cold Dulbecco's modified Eagle's medium (DMEM) when in transit. The tumor sample was rinsed with antibiotic wash, minced, and then digested in collagenase with or without trypsin. Tumor organoids were treated with DNase and separated out by differential centrifugation at 1,500 rpm 3 4-6 spins. Tumor organoids were then allocated to either Matrigel or 3D collagen I and cultured in human mammary epithelium medium containing insulin, EGF, hydrocortisone, and cholera toxin. Medium was replaced every 3 to 4 days.
Statistics. Statistical analysis was conducted using R. For all boxplots, the whiskers represent the 5th and 95th percentiles. All tests used and p values are specified in the FIG. legends. p<0.05 was considered significant. Additional materials and methods, including isolation of tumor organoids, antibodies, and staining procedures used, are described in the Extended Experimental Procedures.
Antibodies and Immunofluorescence.
For immunofluorescence of tumor organoids cultured in 3D gels, gels were fixed in 4% paraformaldehyde, permeabilized with Triton-X/lx PBS, and blocked in 1×PBS+10% fetal bovine serum and 1% BSA. Primary antibodies were incubated ˜8 hr at room temperature or overnight at 4 C at the dilutions listed below in antibody diluent, 1×PBS+1% fetal bovine serum and 1% BSA. Secondary antibodies coupled to Alexa Fluor 488, 562, or 647 (Invitrogen) were incubated ˜4 hr at room temperature. Where indicated, phalloidin was added at 1:100 dilution to stain F-actin positive cell membranes.
For immunofluorescence experiments of thick tumor tissues (100 mmor greater), tissue organoids were fixed overnight in 4% paraformaldehyde, embedded in OCT, and cut into sections on a cryostat. In this case, primary antibody incubation was performed in antibody diluent, for 2 to 3 days at 4 C, followed by secondary antibody incubation for 1 to 2 days also at 4 C. Overlapping z-stacks were captured using a high speed confocal spinning disc microscope, and the z-stacks were assembled using Fiji software, and custom scripts. To estimate the relative distance of cell populations from the tumor-stromal border, pixels were classified as K14+, K14− (mTomato+K14-), or stroma (F-actin+mTomato-). For each K14+ or K14-pixel we then identified the nearest neighboring stromal pixel. Using Fiji software, we calculated the Euclidian distance map. Then using R software, we tabulated the total number of pixels at any given distance from stroma. All custom scripts available upon request.
Primary antibodies were Cytokeratin 14 (Covance, PRB-155P), Cytokeratin 5 (Covance, PRB-160P), p63 (Epitomics, 5353-1, or Santa-Cruz, sc-8431), SMA (Sigma, A5228), K8 (TROMA-1c) (Developmental Studies Hybridoma Bank, 386-113626), K18 (Epitomics, 1924-1), P-cadherin (Life Technologies, Clone PCD-1 or Novus, NBP1-59222), Myhll (Santa-Cruz, sc-6956), E-cadherin (Invitrogen, 13-1900), Phospho-histone H3 (Ser10) (Cell Signaling Technologies, #9701), and Calponin (Millipore, 04-589).
Immunohistochemistry of Primary Human Tumor Sections.
K14 protein expression was evaluated in formalin-fixed paraffin-embedded primary tumors by immunohistochemistry in accordance to IRB protocol NA—00003308. Five-mm sections were treated with DAKO target retrieval solution for 20 min according to the manufacturer's recommendations and then incubated for 1 hr with an anti-human-K14 rabbit polyclonal antibody (Covance PRB-155P) at a concentration of 2.5 mg/ml, using an automated slide stainer (DAKO). Secondary reagents (LSAB2 secondary reagent system) were supplied by DAKO and used according to the manufacturer's specifications.
The intensity of staining in the cancer cells was scored as +(low to no staining), ++, or +++(intense staining). The pattern of staining was scored as primarily cytoplasmic or cytoskeletal with or without enrichment at the border of collective invasive units. Scoring was conducted in a blinded manner by a pathologist observer (EG). The breast cancer subtype was determined for each specimen according to St. Gallen Consensus Guidelines using surrogate IHC criteria, including estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67 status (Goldhirsch et al., 2013). Lumenal A tumors were defined as those that were ER positive and Her2 negative and had PR>20% and Ki-67<20%. Lumenal B tumors were defined as those tumors that were ER positive and any of the following: PR % 20%, Ki-67 R 20%, or Her2 amplified. TNBC tumors were defined as those tumors that were negative for ER, PR, and Her2.
Isolation and 3D Culture of Murine Organoids.
We isolated organoids from primary mammary tumors and normal mammary gland using previously described techniques (Nguyen-Ngoc et al., 2012). MMTV-PyMT tumors were harvested from mice at 12-16 weeks of age, C3(1)-Tag tumors were harvest at 22-24 weeks of age, and MMTV-Neu tumors were harvested at 40-50 weeks of age, coinciding with palpable solid tumors. For each mouse, we surgically isolated the largest tumor and processed it as above. Briefly, we dissected tissue into epithelial organoids by a combination of mechanical and collagenase/trypsin digestion. We then separated these organoids from single cells by differential centrifugation. Any incompletely digested large tumor organoids were removed prior to differential centrifugation. We also added additional rounds of differential centrifugation as needed to remove single cells. The final pellet was composed of epithelial organoids, each containing 200-1000 cells.
We then embedded organoids in type I rat tail collagen gels (BD Biosciences 354236) or 3D Matrigel (BD Biosciences 354230). All cultures were set up in 24-well coverslip bottom plates (E&K Scientific EK-42892), or 2-well or 4-well coverslip bottom chambers (Nunc 155383). Acid solubilized rat tail collagen I gels (3 mg/ml collagen I, pH 7-7.5) were prepared as previously described (Nguyen-Ngoc et al., 2012). For each matrix, organoids were mixed to yield a suspension of 1-2 organoids/ml. A 100 ml suspension of organoids was plated in each well on the 37° C. heating block, followed by incubation at 37° C. to allow polymerization. All murine samples were cultured in 1 ml of 2.5 nM FGF2 in murine organoid media.
Image Acquisition and Quantification.
Confocal images were acquired using a custom spinning disc microscope using a 40× cAPO oil objective. For z-stacks, 2 mm spacing was used. Representative single z planes are presented unless noted. Images were recorded at 1,024×1,024 square pixels representing 0.17 mm per pixel. Second-harmonic generation microscopy was conducted using a Zeiss LSM 710 laser-scanning microscope at 63× water objective. Red-green-blue (RGB) images were assembled using Fiji software and custom scripts.
Time-Lapse Imaging.
Live differential interference contrast (DIC) imaging of tumor organoids was conducted using a Zeiss Cell Observer system with a Zeiss AxioObserver Z1 and a AxioCam MRM camera. In general, images were collected at 20 min intervals with exposure times of ˜250 ms. Live confocal time-lapse imaging was performed using a custom spinning disc microscope (Ewald, 2013). Temperature was held at 37° C. and CO2 at 5%.
Flow Cytometry.
Primary tumors from MMTV-PyMT mice carrying a K14-GFP reporter were harvested for tumor organoids. Organoids were subsequently digested down to single cell suspensions in trypsin-versene according to established protocols (Smalley, 2010). Cells were resuspended in HBS8% BSA. The resulting cell suspensions were filtered through 100 mm cell strainers and analyzed on a BD FACSAria or a Beckman-Coulter MoFlo Cytometer. Dead cells were excluded by propidium iodide fluorescence.
Basal and Myoepithelial Gene Expression.
mRNA expression from relevant probes were identified from a previously published microarray data set by our laboratory (Nguyen-Ngoc et al., 2012). Normal mammary epithelial organoids and mammary tumor epithelial organoids were cultured in 3D collagen for 4 days and harvested for mRNA. Each sample represented at least 3 independent biologic replicates. Sample preparation, labeling, and array hybridizations were performed according to standard protocols from the UCSF Shared Microarray Core Facilities and Agilent Technologies (http://www.arrays.ucsf.edu and http://www.agilent.com). Equal amounts of Cy3-labeled target were hybridized to Agilent whole mouse genome 4×44K Ink-jet arrays (Agilent). Arrays were scanned using the Agilent microarray scanner (Agilent), and raw signal intensities were extracted with Feature Extraction v9.1 software (Agilent). Microarray data was deposited to the NCBI GEO repository and are accessible through GEO series accession number GSE39173.
Oxytocin Contractility Experiment.
Normal mammary epithelial organoids and MMTV-PyMT tumor organoids were embedded in 3D collagen I matrix and cultured in FGF2 organoid media for 4 days. Normal and tumor organoids were then monitored by DIC time-lapse microscopy collecting images every 5 min. Oxytocin (Sigma, 03251) was dissolved to a final concentration of 5 and 50 nM in FGF2 organoid media. The medium was replaced for normal and tumor samples and contraction was observed by time-lapse imaging, again collecting images every 5 min. The area defined by the tissue organoid boundary pre- and postoxytocin treatment was measured using Zeiss software, and plotted using R and the ggplot2 package.
Second Harmonic Generation Microscopy to Measure Collagen Fiber Density.
Tumor sections from 8 tumors were stained for K14, phalloidin and collagen IV. Confocal sections from optically cleared specimens were imaged on a Zeiss 710 with a Chameleon laser set to 880 nm, set to max pinhole. Random fields were collected at 25× resolution and classified into one of three morphologies: K14+ cells with invasive morphology, K14+ cells with noninvasive morphology, or K14− regions. Mean pixel intensity for SHG and collagen IV channels were then determined in Fiji using a custom macro. We defined the zero point to be the mean pixel intensity averaged over all K14− regions, which did not express collagen IV and had weak SHG signal. Mean pixel intensities were then plotted in R using ggplot and are presented as box-plots. Statistics were determined using an unpaired two-sided t test.
Matrix Switching Experiments.
MMTV-PyMT; K14-GFP; mT/mG tumor organoids were cultured in 3D Matrigel for four days, and then freed from the gel by gentle agitation and resuspension in DMEM. Intact tumor organoids were spun down by differential centrifugation and re-embedded in 3D collagen I. Fluorescent tumor organoids were then imaged used a spinning disc confocal microscope in time-lapse mode with membrane Tomato outlining cell membranes, and GFP marking K14+ cells.
Lentiviral Transduction of Tumor Organoids.
Under standard conditions, epithelial organoids have extremely low lentiviral transduction efficiency. We achieved efficient viral transduction in mammary epithelium by using a magnet-based approach, in which magnetic bead-coupled virus is brought into direct contact with organoid structures (Oz Biosciences). Lentiviral particles encoding shRNAs against luciferase, K14, and p63 were purchased at a titer of 1×10a6 PFU/ml from the MISSION pLKO library (Sigma). Organoids were infected with lentivirus in complex with magnetic nanoparticles, and after a 1-day growth period, were selected with puromycin to enrich for shRNA expressing cells. Selected organoids were then harvested for western blotting or embedded in 3D collagen for time-lapse DIC microscopy.
Mammary Fat Pad Transplantation.
Tumor organoids were harvested and either directly transplanted the following morning or infected and selected following lentiviral transduction. Mammary organoid transplantation was conducted using a JHU IACUC approved protocol. 3-4 week old congenic FVB host mice were anesthetized with isofluorane. Following a midline excision, each #4 mammary gland was exposed, cleared of the fat pad extending to the mammary lymph node, and ˜300-500 organoids either in 20 ml of DMEM or 50:50 DMEM/Matrigel were transplanted into the residual fat pad. Cleared areas were treated with bupivicane for analgesia, and the mouse was closed up with surgical staples. Mice were followed for recovery every day for 1 week, and monitored twice weekly thereafter for tumor growth. Mice were generally harvested with tumors exceeding 1 cm in size.
An Ex Vivo 3D Culture Assay Identifies Invasive Cells within Primary Tumors.
We developed a 3D primary culture model (Nguyen-Ngoc et al., 2012) that enabled us to observe cell behaviors during collective invasion and to interrogate the molecular phenotype of the most invasive cells (
We first characterized invasion in organoids derived from a genetically engineered mouse model of breast cancer in which the mouse mammary tumor virus long terminal repeat drives expression of the polyoma virus middle T oncogene (MMTVPyMT) (Guy et al., 1992a). MMTV-PyMT mice develop highly invasive mammary tumors that metastasize spontaneously to the lung (Lin et al., 2003). By gene expression profiles, MMTVPyMT tumors cluster with the aggressive lumenal B subtype of human breast cancer (Herschkowitz et al., 2007). Tumor organoids isolated from this model progressively extended multicellular strands of cancer cells into the collagen I over 48-72 hr (
Invasive Leader Cells Are Molecularly Distinct and Express Basal Epithelial Markers.
We were able to determine the molecular phenotype of invasive leader cells unambiguously due to their position at the front of invasive strands and their distinct protrusive morphology. Our analysis defined four molecular features of leader cells in this lumenal mouse model. First, leader cells preferentially expressed multiple basal epithelial markers, including cytokeratin-14 (K14), p63, P-cadherin, and cytokeratin-5 (K5) (
K14+ Cells are Enriched at the Invasive Border in Primary Tumor and in Lung Metastases.
We next asked whether K14+ cells also led collective invasion in vivo in this lumenal model. To address this question, we optically reconstructed large regions of the tumor-stromal border from fixed sections of intact tumors. K14+ cells were concentrated at tumor-stromal borders (n=9 reconstructed tumors from 8 mice;
We next asked what fraction of collective invasion in vivo was led by K14+ cells. We employed an orthotopic transplant model to mark donor-derived tumor cells unambiguously. We transplanted MMTV-PyMT mammary tumor organoids coexpressing a red fluorescent reporter (mTomato) into the cleared mammary fat pads of nonfluorescent congenic hosts (FVB) and identified invasive units at the tumor-stromal border, blind to K14 expression (
Because MMTV-PyMT tumors develop metastases with high penetrance, we next quantified the K14 status of their lung metastases. Although K14 was absent in normal lung parenchyma, we observed K14 staining in >88% of metastatic lesions, from micrometastases up to large, 500 mm lesions (
K14+ Cells Lead Collective Invasion across Multiple Mouse Models of Breast Cancer.
To test the generality of our observations, we next characterized invasion in two additional genetically engineered mouse models of breast cancer: MMTV-Neu, a model of HER2+ lumenal breast cancer, and C3(1)/Tag, a model of basal breast cancer (Guy et al., 1992b; Maroulakou et al., 1994). Tumor organoids isolated from these models displayed pronounced differences in the morphologic patterns and timing of invasion in 3D culture (
K14+ Cells Lead Collective Invasion in Primary Human Breast Tumors in 3D Culture and In Vivo.
To validate our observations from mouse models, we next characterized invasive leader cells in fresh human breast tumor specimens. We isolated organoids from primary tumor tissue obtained at initial breast surgery (n=10;
We therefore hypothesized that K14+ cells would lead collective invasion in primary human breast tumors in vivo. We first examined fixed sections from intact tumor specimens corresponding to three cases from 3D culture. We observed that K14+ cells led collective invasion in each case (
We observed strong K14 staining (CK3) in collective invasive fronts in lumenal A, lumenal B (both HER2- and HER2+), and triple-negative breast cancers (
Lumenal Tumor Cells Acquire Markers of Basal Differentiation.
To address how K14+ leaders are generated, we asked when K14 was expressed in 3D culture of MMTV-PyMT tumor organoids. Consistent with the low in vivo frequency of K14+ cells in this lumenal mouse model, tumor organoids were initially K8+, with few K14+ cells. During the first 48 hr of culture, the number of K14+ cells and p63+ cells in tumor organoids increased significantly (
One possible cellular mechanism for the expansion of K14+ cells is cell proliferation. However, the number of mitotically active (pH3+) K14− cells was significantly greater than the number of mitotically active K14+ cells during the first 2 days of culture (
Alternatively, lumenal tumor cells may convert directly from K14− to K14+ states. To test this hypothesis directly, we generated MMTV-PyMT mice carrying a K14 promoter biosensor in which GFP reports on K14 gene expression (Vaezi et al., 2002). In these tumor organoids, we observed individual cells at the basal surface transition from K14- to K14+ states (
K14+ Cells Acquire Leader Cell Behaviors Specifically in Collagen-I-Rich Local Microenvironments.
We previously demonstrated that ECM composition strongly regulates tumor invasion (Nguyen-Ngoc et al., 2012). Organoids isolated from the same tumor but allocated to different ECMs robustly invaded when cultured in collagen I, but not when cultured in basement membrane gels (Matrigel). We therefore hypothesized that different ECM environments might have a differential capacity to induce the basal gene expression characteristic of invasive leader cells.
To test this hypothesis, we cultured MMTV-PyMT tumor organoids in 3D Matrigel. Although tumor organoids were noninvasive in Matrigel (
If phenotypic conversion induces a stable change in invasive potential, then switching to an invasive microenvironment should induce an acute change in K14+ cell behavior. To test this hypothesis, we conducted a matrix-swapping experiment. We cultured PyMT tumor organoids in 3D Matrigel for 4 days, liberated organoids from the gel, and re-embedded them in collagen I. Under these conditions, there was rapid collective invasion from the basal layer within 12 hr (
In vivo, we observed that, although K14+ cells led collective invasion, there were also K14+ cells with noninvasive morphology (
Basal Epithelial Genes K14 and p63 are Required for Collective Invasion in 3D Culture.
We next asked whether expression of basal epithelial genes by leader cells is functionally required for collective invasion. Accordingly, we developed protocols for efficient lentiviral transduction of primary tumor organoids. We tested five different small hairpin RNAs (shRNAs) targeting K14 and p63 and determined the two hairpins with the highest knockdown efficiency by western blotting (
To assess the requirement for K14 in collective invasion, we cultured Luc-kd, K14-kd1, and K14-kd2 tumor organoids in 3D collagen I and observed them by time-lapse differential interference contrast (DIC) microscopy. Control Luc-kd organoids strongly expressed K14 and invaded vigorously into collagen I matrix (
We next examined the phenotypic consequences of p63 knockdown (p63-kd1 and p63-kd2) in PyMT primary tumor organoids cultured in collagen I (
In Vivo Knockdown of K14 Disrupts Collective Invasion at the Tumor-Stromal Border.
We next sought to test the requirement for K14 in collective invasion in vivo. We isolated tumor organoids from fluorescently labeled advanced carcinomas (mTomato+; MMTV-PyMT), transduced them with Luc-kd, K14-kd1, or K14-kd2 lentivirus, and then orthotopically transplanted the transduced organoids into the cleared mammary fat pads of nonfluorescent congenic hosts (
The transition to invasive behavior in epithelial cancer cells is a critical step in metastasis, yet both the cellular and molecular basis of this transition is incompletely understood. An important challenge is that primary tumors are complex heterogeneous tissues containing phenotypically and genetically distinct cancer cell subpopulations interacting with an altered extracellular matrix and diverse stromal cells (Almendro et al., 2013; Egeblad et al., 2010a, 2010b; Fidler, 2003; Weigelt and Bissell, 2008). It is important to reduce this complexity to specific molecular regulators of tumor cell behavior in order to identify targets for therapeutic intervention.
To accomplish this goal, we developed a general strategy for identifying the most invasive cells in a primary epithelial tumor. We then applied this strategy and discovered that the most invasive cancer cells are behaviorally and molecularly distinct from bulk tumor cells. Importantly, the invasive leader cells expressed basal epithelial genes, including K14 and p63, across mouse models of breast cancer and in diverse human breast tumors. Cells with this phenotype led the majority of collective invasion in vivo and were strongly overrepresented in lung metastases. We therefore have exploited our assays to resolve the heterogeneous cancer cell populations within the primary tumor into functional classes based on their invasive behavior. We then leveraged this understanding to establish the requirement for K14 and p63 for collective invasion in primary cells derived from poorly differentiated carcinomas.
Previous studies have shown that heterotypic epithelial-stromal interactions contribute to cancer invasion in diverse malignancies (Condeelis and Pollard, 2006; Gaggioli et al., 2007). Our data establish the importance of heterotypic epithelial epithelial interactions between different cancer cell subpopulations in collective invasion Importantly, although invasive leader cells were highly protrusive and migratory, they retained characteristically epithelial expression of cell adhesion proteins (e.g., E-cadherin) and intermediate filament proteins (e.g., K14, K8) during invasion.
K14 expression also marks other highly migratory epithelial cell populations. During development, the migratory cells of the normal mammary embryonic placode are K14+K8+SMA− (Moumen et al., 2011; Sun et al., 2010). Similarly, the highly invasive rat breast cancer MTLn3 cell line is K14+K8+, whereas noninvasive MTCs do not express these markers (Lichtner et al., 1991). Likewise, highly invasive human breast cancer cell lines MDA-MB-468, MDA-MB-436, and BPLER are K14+K18+, whereas cell lines with low invasive potential, such as MCF-7, T47D, and ZR75 express a pure lumenal phenotype (Gordon et al., 2003; Petrocca et al., 2013). Experimental models suggest that basal breast cancers arise from lumenal progenitors and that mutations in genetic drivers of breast cancer, such as BRCA1, can shift lumenal progenitors toward basal differentiation (Lim et al., 2009; Molyneux et al., 2010). Consistent with these observations, a number of pathologic studies have shown that basal cytokeratins, including K14, are associated with poor patient prognosis, early relapse, and reduced overall survival (de Silva Rudland et al., 2011; Gusterson et al., 2005; Laakso et al., 2006; Malzahn et al., 1998). Our study provides a biological basis for these findings, namely that K14 marks a subpopulation of tumor cells capable of initiating collective invasion, a critical step in metastatic progression.
Importantly, we directly observed phenotypic conversion of K14− lumenal tumor cells to K14+ cells with invasive potential. We previously demonstrated that collective invasion is strongly regulated by the composition of the local extracellular matrix (Nguyen-Ngoc et al., 2012). In the present study, we demonstrated that the basal invasive program can be induced in diverse ECM microenvironments. However, consistent with our prior study, basal gene expression was only associated with invasive cell behaviors and morphologies in collagen-I-rich microenvironments in 3D culture and in vivo.
In our study, we established that the basal epithelial intermediate filament cytoskeleton is specifically required for collective invasion in cancer. Our data suggest that actin-based subcellular protrusions and multicellular collective invasion can be uncoupled and have distinct cytoskeletal requirements. The precise mechanism by which cytokeratin 14 regulates collective invasion, be it directly modifying the tensile strength and viscoelastic properties of the cell (Yamada et al., 2002), regulating cell-cell adhesion (Weber et al., 2012), or by signal transduction mechanisms independent of their mechanical properties (Kim et al., 2006), remains unclear and warrants further study. Because cells with basal differentiation are found in many epithelial organs, our findings may also have implications for invasion in other solid tumors.
Generation of an HCC Organoid 3D Model.
Based on our past experience with breast tumors, we developed methods to isolate and culture organoids derived from primary hepatocellular carcinomas (HCC). Briefly, we surgically remove the tumor, chop coarsely with a sterile razor blade, incubate with collagenase and trypsin, then separate the epithelial organoids from the stromal single cells by differential centrifugation (
We observed microenvironment specific invasion. In Matrigel, HCC tumors were indolent. In collagen I gels, HCC organoids invaded vigorously. Collagen I represents the more appropriate model for the fibrotic conditions associated with HCC in patients. We can also incorporate tumor derived fibroblasts and immune cells and assay for effects on proliferation and invasion.
Only a small minority of the cancer cells in a HCC in vivo are located at the invasive edge (
This application claims the benefit of U.S. Provisional Application No. 61/915,050, filed Dec. 12, 2013, and U.S. Provisional Application No. 61/822,713, filed May 13, 2013, each of which are incorporated herein by reference in their entireties.
This invention was made with U.S. government support under grant no. P50CA088843, grant no. U01CA155758, grant no. P50CA103175, and grant no. W81XWH-12-1-0018. The U.S. government has certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 61822713 | May 2013 | US | |
| 61915050 | Dec 2013 | US |
